These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 34242798)

  • 1. Novel rapid-acting glutamatergic modulators: Targeting the synaptic plasticity in depression.
    Wang YT; Wang XL; Feng ST; Chen NH; Wang ZZ; Zhang Y
    Pharmacol Res; 2021 Sep; 171():105761. PubMed ID: 34242798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments.
    Kadriu B; Musazzi L; Henter ID; Graves M; Popoli M; Zarate CA
    Int J Neuropsychopharmacol; 2019 Feb; 22(2):119-135. PubMed ID: 30445512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting metaplasticity mechanisms to promote sustained antidepressant actions.
    Brown KA; Gould TD
    Mol Psychiatry; 2024 Apr; 29(4):1114-1127. PubMed ID: 38177353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid-onset antidepressant efficacy of glutamatergic system modulators: the neural plasticity hypothesis of depression.
    Wang J; Jing L; Toledo-Salas JC; Xu L
    Neurosci Bull; 2015 Feb; 31(1):75-86. PubMed ID: 25488282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New targets for rapid antidepressant action.
    Machado-Vieira R; Henter ID; Zarate CA
    Prog Neurobiol; 2017 May; 152():21-37. PubMed ID: 26724279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status.
    Henter ID; Park LT; Zarate CA
    CNS Drugs; 2021 May; 35(5):527-543. PubMed ID: 33904154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting metabotropic glutamate receptors for rapid-acting antidepressant drug discovery.
    Musazzi L
    Expert Opin Drug Discov; 2021 Feb; 16(2):147-157. PubMed ID: 32962432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity.
    Gerhard DM; Wohleb ES; Duman RS
    Drug Discov Today; 2016 Mar; 21(3):454-64. PubMed ID: 26854424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Encoding, Consolidation, and Renormalization in Depression: Synaptic Homeostasis, Plasticity, and Sleep Integrate Rapid Antidepressant Effects.
    Rantamäki T; Kohtala S
    Pharmacol Rev; 2020 Apr; 72(2):439-465. PubMed ID: 32139613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the dysfunction of glutamate receptors for the development of novel antidepressants.
    Xia CY; He J; Du LD; Yan Y; Lian WW; Xu JK; Zhang WK
    Pharmacol Ther; 2021 Oct; 226():107875. PubMed ID: 33901503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of glutamate on the action of antidepressants.
    Hashimoto K
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1558-68. PubMed ID: 20600468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glutamatergic receptor and neuroplasticity in depression: Implications for ketamine and rapastinel as the rapid-acting antidepressants.
    Wang YT; Zhang NN; Liu LJ; Jiang H; Hu D; Wang ZZ; Chen NH; Zhang Y
    Biochem Biophys Res Commun; 2022 Feb; 594():46-56. PubMed ID: 35074585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roles of glutamate signaling in preclinical and/or mechanistic models of depression.
    Tokita K; Yamaji T; Hashimoto K
    Pharmacol Biochem Behav; 2012 Feb; 100(4):688-704. PubMed ID: 21536063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance of Exploring N-Methyl-D-Aspartate (NMDA) as a Future Perspective Target in Depression.
    Bhatia NY; Ved HS; Kale PP; Doshi GM
    CNS Neurol Disord Drug Targets; 2022; 21(10):1004-1016. PubMed ID: 35352638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mGlu2/3 Receptor Antagonists as Novel Antidepressants.
    Chaki S
    Trends Pharmacol Sci; 2017 Jun; 38(6):569-580. PubMed ID: 28413097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological properties of glutamatergic drugs targeting NMDA receptors and their application in major depression.
    Serafini G; Pompili M; Innamorati M; Dwivedi Y; Brahmachari G; Girardi P
    Curr Pharm Des; 2013; 19(10):1898-922. PubMed ID: 23173582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mGlu receptors as potential targets for novel antidepressants.
    Chaki S; Fukumoto K
    Curr Opin Pharmacol; 2018 Feb; 38():24-30. PubMed ID: 29486373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder.
    Niciu MJ; Ionescu DF; Richards EM; Zarate CA
    J Neural Transm (Vienna); 2014 Aug; 121(8):907-24. PubMed ID: 24318540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Treatment Strategies of Depression: Based on Mechanisms Related to Neuroplasticity.
    Huang YJ; Lane HY; Lin CH
    Neural Plast; 2017; 2017():4605971. PubMed ID: 28491480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder.
    Jaso BA; Niciu MJ; Iadarola ND; Lally N; Richards EM; Park M; Ballard ED; Nugent AC; Machado-Vieira R; Zarate CA
    Curr Neuropharmacol; 2017; 15(1):57-70. PubMed ID: 26997505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.